EcoDrugPlus

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSPSNG00000014080
Gene Symbol: AGTR2
3 Cross references
191 Possible Orthologues:

Apelin Receptor

Ensembl ID : ENSPSNG00000013960
Gene Symbol: APLNR
3 Cross references
171 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSPSNG00000001681
Gene Symbol: APH1A
2 Cross references
137 Possible Orthologues:

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSPSNG00000000505
Gene Symbol: APH1B
3 Cross references
190 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSPSNG00000012191
Gene Symbol: APEX1
3 Cross references
212 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s Type

Ensembl ID : ENSPSNG00000017879
Gene Symbol: ALOX12
3 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSPSNG00000018096
Gene Symbol: ALOX5
3 Cross references
219 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSPSNG00000012197
Gene Symbol: ALOX5AP
3 Cross references
200 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSPSNG00000006629
Gene Symbol: AVPR1A
1 Cross references
264 Possible Orthologues:

Arginine Vasopressin Receptor 1b

Ensembl ID : ENSPSNG00000018076
Gene Symbol: AVPR1B
3 Cross references
134 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSPSNG00000021500
Gene Symbol: AVPR2
1 Cross references
231 Possible Orthologues:

Aromatase

Ensembl ID : ENSPSNG00000003922
Gene Symbol: LOC116749060
2 Cross references
306 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).